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an annual mean additional 42.1 outpatient consultations (95%
CI: 36.4–57.9) and 2.4 inpatient days (95% CI: 1.2–3.6). This
resulted in an estimated increase in health expenditures of $3140
CAN (95% CI: 2052–4225). CONCLUSION: Using high quality
administrative health data we found that, among individuals
living in Vancouver’s DTES (Canada’a poorest postal code),
infection with HIV resulted in increased mean utilization of
health services and expenditures. This has implications for social
and health conditions associated with poverty in communities
with high HIV prevalence. The quantitative estimates can be
useful when evaluating programs designed to prevent and treat
HIV amongst persons living in impoverished areas.
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OBJECTIVES: Rituximab maintenance therapy (RM) has been
shown to signiﬁcantly extend overall survival (OS) and pro-
gression free survival (PFS) in relapsed/refractory follicular
lymphoma (FL) in the pivotal trial EORTC20981. The purpose
of this study was to assess, from the French Sickness Funds
perspective, cost-effectiveness and cost-utility of RM after
induction therapy versus current standard practice (observation).
METHODS: A 3 health state lifetime transition model (30 years)
was developed comparing RM and observation (Obs). PFS and
OS were derived from the trial EORTC20981 with a median
follow-up of 28 months and extrapolated from 2-year Kaplan-
Meier curves using a Weibull distribution and were conserva-
tively assumed to last only 5 years. Utility data were derived from
a multicentric observational study using the EQ-5D question-
naire. Direct medical costs derived from French ofﬁcial sources.
Costs were discounted at 3% and sensitivity analyses were per-
formed. RESULTS: RM is effective in the management of
relapsed/resistant FL. The results showed that life expectancy
and QALY were increased respectively by 22% and 30% in
patients treated with RM. Incremental cost-effectiveness ratio
(ICER) was €7,612 per life year gained. The cost per QALY
gained was €8,729. In one-way sensitivity analysis most of ratios
fell within the range of €7,000 to €12,000 (the ICERs ranged
from €5,700 to €43,300 per LYG and from 6,800€ to €49,700
per QALY). The frequency and cost of treatments upon relapse
were identiﬁed as drivers for the model. Palliative care, transpor-
tation and indirect costs such as productivity loss were not
included in the analysis. It was a conservative approach because
it was expected that patients under RM would have less relapse
and better life expectancy than those in observation. CONCLU-
SION: RM is a cost-effective strategy in the management of
relapsed/refractory FL in France with an ICER largely below the
threshold commonly cited in such analysis.
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